-
Views
-
Cite
Cite
NORMAN ROSENTHAL, KARL L. INSOGNA, J. WARD GODSALL, ALFREDO GAC, LAURIE SMALDONE, JAMES A. WALDRON, ANDREW F. STEWART, Elevations in Circulating 1,25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia, The Journal of Clinical Endocrinology & Metabolism, Volume 60, Issue 1, 1 January 1985, Pages 29–33, https://doi.org/10.1210/jcem-60-1-29
- Share Icon Share
Abstract
Three patients with hypercalcemia associated with malignant lymphoma and elevations in plasma 1,25-dihydroxyvitamin D [1,25-(OH)2D] are described. In addition to the elevation of circulating 1,25-(OH)2D, these three patients were characterized by suppressed immunoreactive PTH levels and urinary cAMP excretion, elevated fasting urinary excretion of calcium, and absence of adenylate cyclase-stimulating activity in the tumor extracts. Bone marrow biopsy and skeletal radionuclide scans were negative for lymphoma in two patients. Surgical excision of a solitary splenic lymphoma in one patient and medical therapy in another patient resulted in rapid normalization of the serum calcium and plasma 1,25-(OH)2D levels.
These findings confirm an earlier observation that elevated plasma levels of 1,25-(OH)2D may occur in certain patients with lymphoma and suggest that this vitamin D metabolite may act as a humoral or systemic mediator of hypercalcemia. Proof that this is the case and identification of the source of 1,25-(OH)2D production will require further study.